Massimo Levrero
Overview
Explore the profile of Massimo Levrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
5541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caussy C, Verges B, Leleu D, Duvillard L, Subtil F, Abichou-Klich A, et al.
Diabetes Care
. 2025 Jan;
PMID: 39887699
Objective: Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of noninvasive tests (NITs) with...
2.
Dahboul F, Sun J, Buchard B, Abeywickrama-Samarakoon N, Pujos-Guillot E, Durand S, et al.
Liver Int
. 2025 Jan;
45(2):e70006.
PMID: 39840890
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of hepatocellular carcinoma (HCC). In this study, we combine metabolomic and gene expression analysis to compare...
3.
Degasperi E, Scholtes C, Testoni B, Uceda Renteria S, Anolli M, Charre C, et al.
J Hepatol
. 2024 Dec;
PMID: 39662705
Background & Aims: Serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels have been proposed as useful biomarkers in the management of patients with HBV; however, their role in...
4.
Roca Suarez A, Plissonnier M, Michelet M, Dubois A, Heintz S, Saez-Palma M, et al.
STAR Protoc
. 2024 Oct;
5(4):103359.
PMID: 39368096
The liver microenvironment contains a wide variety of monocyte and macrophage populations. Here, we present a protocol for the specific isolation of liver-resident macrophages, known as Kupffer cells (KCs), from...
5.
Paturel A, Casuscelli di Tocco F, Bousquet D, Plissonnier M, Grand X, Tak H, et al.
JHEP Rep
. 2024 Sep;
6(10):101124.
PMID: 39328324
Background & Aims: Circulating HBV RNAs have been proposed as a biomarker that reflects the transcriptional activity of covalently closed circular DNA (cccDNA) and may help to evaluate HBV treatment...
6.
Lau D, Jackson K, Picchio C, Kramvis A, Sonderup M, Lemoine M, et al.
Lancet Gastroenterol Hepatol
. 2024 Sep;
9(12):1073-1076.
PMID: 39305916
No abstract available.
7.
Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier M, Faure-Dupuy S, et al.
JHEP Rep
. 2024 Sep;
6(10):101128.
PMID: 39290403
Background & Aims: Although most hepatocellular carcinoma (HCC) cases are driven by hepatitis and cirrhosis, a subset of patients with chronic hepatitis B develop HCC in the absence of advanced...
8.
Dargaud Y, Levrero M, Bailly F, Lienhart A, Zoulim F
Thromb Res
. 2024 Jun;
240:109064.
PMID: 38878740
Gene therapy for hemophilia is a groundbreaking treatment approach with promising results and potential to reduce the burden of the disease. However, uncertainties remain, particularly regarding the liver side effects...
9.
Chouik Y, Aubin A, Maynard-Muet M, Segrestin B, Milot L, Hervieu V, et al.
Obesity (Silver Spring)
. 2024 May;
32(6):1114-1124.
PMID: 38699960
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with obesity. We aimed to assess the impact of obesity on the performance of different noninvasive tests, including liver stiffness...
10.
Roca Suarez A, Plissonnier M, Grand X, Michelet M, Giraud G, Saez-Palma M, et al.
Gut
. 2024 May;
73(12):2012-2022.
PMID: 38697771
Objective: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in...